Appointment of Joint
Corporate Broker
Oxford, UK - 15 February 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the
Company"), a quality and innovation-led cell and gene therapy CDMO,
today announces the appointment of RBC Capital Markets as the
Company's joint corporate broker, to work alongside J.P.Morgan
Cazenove, with immediate effect.
-Ends-
Enquiries:
Oxford Biomedica
plc:
Sophia Bolhassan, VP, Corporate Affairs and IR - T:
+44 (0) 7394 562 425 / E: ir@oxb.com
ICR
Consilium:
T: +44 (0)20 3709 5700 / E:
oxfordbiomedica@consilium-comms.com
Mary-Jane Elliott / Matthew Neal / Davide Salvi
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a
quality and innovation-led cell and gene therapy CDMO with a
mission to enable its clients to deliver life changing therapies to
patients around the world.
One of the original pioneers in cell
and gene therapy, the Company has more than 25 years of experience
in viral vectors; the driving force behind the majority of gene
therapies. The Company collaborates with some of the world's most
innovative pharmaceutical and biotechnology companies, providing
viral vector development and manufacturing expertise in lentivirus,
adeno-associated virus (AAV), adenoviral vectors, and other viral
vector types. Oxford Biomedica's world-class capabilities span from
early-stage development to commercialisation. These capabilities
are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.
Oxford Biomedica, a FTSE4Good
constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK, Lyon and Strasbourg,
France, and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn
and YouTube.
